A revolutionary dental technology developed by TriAgenics may soon offer a promising alternative to the common, often painful procedure of wisdom teeth removal. The company’s innovative Zero3 Tooth Bud Ablation (TBA) technology aims to prevent wisdom teeth from forming in the first place, potentially reducing the risks and complications associated with traditional extractions.
Wisdom teeth extraction is a routine procedure but comes with potential risks. Common complications include dry sockets, excessive bleeding, and even more severe issues such as nerve damage. In rare cases, it can lead to life-threatening complications. Nearly 30% of patients experience bleeding during the procedure, and some have reported permanent nerve damage, affecting the lower lip, chin, and gums.
TriAgenics’ Zero3 TBA technology focuses on children aged 6 to 12, a time when early signs of wisdom teeth can be detected. The procedure is minimally invasive and highly precise, targeting and neutralizing the developing tooth bud tissue before it becomes problematic third molars. The company reports that each tooth bud can be treated in just 60 to 90 seconds, with all four tooth buds completed in about 30 minutes.
The market potential for this new technology is significant. Approximately 85% of all wisdom teeth will eventually require removal. TriAgenics estimates that its Zero3 TBA product could capture a total addressable market worth more than $2.5 billion annually.
TriAgenics has already conducted extensive research and development, with animal trials showing a 100% success rate in preventing wisdom tooth formation. The company is currently seeking FDA clearance and aims to begin commercializing the Zero3 TBA technology by 2025. Licensed dentists will perform the procedure, using custom 3TBA guides created by TriAgenics for each patient.
To date, the company has raised over $11.5 million in capital and secured 32 U.S. and international patents, including expanded patent coverage in Australia, Canada, Europe, and Mexico. This strong patent portfolio, coupled with growing interest from oral surgeons and pediatric dental specialists, positions TriAgenics as a potential leader in the future of dental care.
Dr. Leigh Colby, TriAgenics CEO, expressed optimism about the impact of the technology, stating, “Dental practitioners are excited about the possibility of eliminating the complications that come with wisdom teeth removal. We believe this will become the standard of care by 2030.”
If successful, the Zero3 TBA technology could mark a major shift in dental care, offering a preventive approach that would spare millions of people from the pain, risks, and expenses linked to wisdom teeth extraction. This innovation has the potential to change not just one procedure, but also set a new standard in preventive dental care, greatly reducing the need for invasive surgeries.
As TriAgenics moves closer to FDA approval and market launch, the dental industry is paying close attention. The success of this technology could bring less pain, fewer risks, and significant cost savings for patients, while transforming the way dental care is delivered.